2023-05-03T22:03:22+00:00 2022-06-30 346565596 ERNST & YOUNG US LLP 4365 EXECUTIVE DRIVE SUITE 1600 SAN DIEGO CA 92121 990 2021-07-01 510197108 SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE SANF 8586463100 10901 NORTH TORREY PINES ROAD LA JOLLA CA 92037 Robin Ryan 858- 8587955244 2023-05-03 true Robin Ryan 999009999 Jocelyne Miller P00634378 8585357200 2023-05-02 2021 2023-04-26 12:10:37Z David Brenner 10901 NORTH TORREY PINES ROAD LA JOLLA CA 92037 221274043 false X WWW.SBPDISCOVERY.ORG X 1976 CA SEE SCHEDULE O 16 15 645 15 1538895 0 111444313 82047252 853344 806855 8321052 19247469 4108275 5201458 124726984 107303034 0 0 0 0 58840604 59973447 0 0 1233396 50083471 46807632 108924075 106781079 15802909 521955 337147969 289830509 76437099 70200509 260710870 219630000 SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE CONDUCTS WORLD-CLASS, COLLABORATIVE RESEARCH DEDICATED TO FINDING CURES FOR HUMAN DISEASE, IMPROVING THE QUALITY OF LIFE, AND THUS CREATING A LEGACY FOR ITS EMPLOYEES, PARTNERS, DONORS, AND COMMUNITY. false false 81977406 0 902176 See Schedule O 81977406 true true false true false false false false true true true false false true true true false false true true false false false false false false false false true true false false false false false false false false false false false false false false false false false false false true 199 0 true 645 true true true false false false false false false false false false true false X 16 15 false false false false false false false true true false false true true true true true true true true false CA CO CT DC FL GA AL HI IL KS KY ME MD MA MI MN MS MO NH NJ NM NY NC ND OH OK OR PA RI SC TN UT VA AR WI X ROBIN RYAN 8586463100 10901 NORTH TORREY PINES RD LA JOLLA CA 92037 C RANDAL MILLS PHD CEO (PART YEAR) 50.0 0.0 X X 1190319 0 268556 JAMES C BLAIR PHD CHAIRMAN 1.0 0.0 X X 0 0 0 KRISTIINA VUORI MD PHD PRESIDENT 50.0 0.0 X X 986151 0 53567 WILLIAM GERHART VICE CHAIRMAN 1.0 0.0 X X 0 0 0 ANNA BARKER PHD TRUSTEE (PART YEAR) 1.0 0.0 X 0 0 0 DANIEL J EPSTEIN TRUSTEE 1.0 0.0 X 0 0 0 DAVID L SZEKERES TRUSTEE 1.0 0.0 X 0 0 0 DAVID W DOWN TRUSTEE 1.0 0.0 X 0 0 0 DONALD B KEARNS PHD TRUSTEE 1.0 0.0 X 0 0 0 DOUGLAS H OBENSHAIN TRUSTEE 1.0 0.0 X 0 0 0 HENRY NORDOFF TRUSTEE (PART YEAR) 1.0 0.0 X 0 0 0 JAMES E JARDON II TRUSTEE 1.0 0.0 X 0 0 0 JAMES M MYERS TRUSTEE 1.0 0.0 X 0 0 0 KAREN S HAYNES TRUSTEE 1.0 0.0 X 0 0 0 KATHERINE CHAPIN TRUSTEE 1.0 0.0 X 0 0 0 KAZUMI SHIOSAKI PHD TRUSTEE 1.0 0.0 X 0 0 0 MATTHEW BROWNE TRUSTEE 1.0 0.0 X 0 0 0 STUART A TANZ TRUSTEE 1.0 0.0 X 0 0 0 WILLIAM A ROPER TRUSTEE 1.0 0.0 X 0 0 0 AMAR DUVVUR CFO 50.0 0.0 X 412421 0 8944 SCOTT TOCHER GENERAL COUNSEL & CORPORATE SECRETARY 50.0 0.0 X 194719 0 7469 CARL WARE PHD CENTER DIRECTOR, IIDC 50.0 0.0 X 450942 0 45465 CHUN JEROLD PHD PROFESSOR 50.0 0.0 X 360136 0 53624 MICHAEL JACKSON PHD DRUG DISCOVERY & DEV, SR VP 50.0 0.0 X 448253 0 60058 RANDAL KAUFMAN PHD PROGRAM DIRECTOR 50.0 0.0 X 378919 0 65980 ZE'EV RONAI PHD CENTER DIRECTOR 50.0 0.0 X 449551 0 68556 4871411 0 632219 105 false true false DPR Construction 1450 Veterans Blvd Redwood City CA 94063 Construction services 1244983 Wilson Sonsini Goodrich & Rosati PO Box 742866 Los Angeles CA 900742866 Legal services 566374 Universal Protection Service LP PO Box 31001-2374 Pasadena CA 921102374 Building security services 370711 Deloitte & Touche LLP PO Box 844708 Dallas TX 75284 Audit services 315935 Rebecca Jorgenson 1757 Sterling Road Waconia MN 55387 Business Consulting Services 269740 10 62674628 19372624 4278 82047252 Shared Services Revenue 541990 806855 806855 0 0 0 0 0 0 806855 3941478 0 0 3941478 3290007 0 0 3290007 277235 0 277235 0 277235 0 0 277235 129277000 113971009 15305991 0 15305991 0 0 15305991 Research 541700 1538895 0 1538895 0 Equipment Proceeds 541990 60609 60609 0 0 Sale of Reagents 541990 28712 28712 0 0 6000 6000 0 0 1634216 107303034 902176 1538895 22814711 2080338 134516 1945822 0 40485652 31224439 8513846 747367 2689720 2115179 564075 10466 11937448 5227156 6619219 91073 2780289 1999330 727325 53634 1392039 209911 1091797 90331 389089 72100 316989 0 412305 0 412305 0 663576 0 663576 0 763880 581804 129388 52688 2020 2000 20 0 5193586 4771381 386349 35856 1392845 937330 409163 46352 7902738 7415941 481228 5569 192838 152811 39851 176 552326 327575 200566 24185 1451168 1362647 87505 1016 6870296 6451208 414279 4809 221813 0 221813 0 RESEARCH SUPPLIES & SVCS 9820069 9820069 0 0 SCIENTIFIC COLLABORATIONS 8751368 8751368 0 0 RECRUITMENT 525227 201824 307176 16227 TUITION FEES 155790 155790 0 0 154659 63027 37985 53647 106781079 81977406 23570277 1233396 0 0 0 0 11192166 9217022 693 5520 7396598 6105380 1378206 2229543 0 0 1888511 2482064 81154 59562 9873188 8294257 164282108 112095670 52155287 52186438 211700816 174605755 39189707 33340626 0 2291643 1304342 337147969 289830509 16002021 15387946 10124024 7819616 47207465 43306541 0 3103589 3686406 76437099 70200509 213091315 179779759 47619555 39850241 260710870 219630000 337147969 289830509 521955 -41602825 0 0 0 0 X false true X true true true X 113630164 108300329 100963692 111444313 82047252 516385750 0 0 113630164 108300329 100963692 111444313 82047252 516385750 4121493 512264257 5346565 5942288 3455907 5237546 7508720 27491026 48551 0 0 0 0 48551 0 0 0 0 0 0 543925327 5417592 0.9418 0.9486 X RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED false false false false false false false false true 1500 1500 false Schedule C, Part II-B, Line 1 DETAILED DESCRIPTION OF THE LOBBYING ACTIVITY DUES TO A RESEARCH AND BIOMEDICAL ORGANIZATION, A PORTION OF WHICH IS CONSIDERED LOBBYING. 23536441 1805 -2492894 497080 20548272 19914852 3687 4470604 852702 23536441 29814541 1005 724999 10625693 19914852 29799743 4000 1337873 1327075 29814541 28681314 502000 1841686 1225257 29799743 0.0 0.684 0.316 false false 12758161 12758161 92041261 59403560 32637701 59482686 52692110 6790576 52186438 PRIVATE EQUITY LPS 10557625 F TOTAL RETURN HEDGE FUNDS 3904898 F SELECT EQUITY FUNDS 18878103 F 33340626 OPERATING LEASE LIABILITIES 1304342 FINANCE LEASE LIABILITIES 2382064 3686406 X 65819000 -41602825 782734 0 -40820091 106639091 663576 367 663943 107303034 106900000 782734 0 782734 106117266 663576 237 663813 106781079 Schedule D, Part V, Line 4 Intended uses of endowment funds INTENDED USES OF THE ORGANIZATION'S ENDOWMENT FUNDS: THE INSTITUTE'S ENDOWMENT FUNDS ARE ESTABLISHED FOR VARIOUS PURPOSES: SCIENTIFIC RESEARCH, CEO CHAIR, PRESIDENTIAL CHAIR, CANCER AND NEUROSCIENCE LEADERSHIP CHAIRS, AND UNRESTRICTED AS TO INCOME. Schedule D, Part X, Line 2 FIN 48 (ASC 740) footnote THE INSTITUTE HAS NO MATERIAL DEFERRED TAX ASSETS OR DEFERRED TAX LIABILITIES RECORDED AS OF JUNE 30, 2022 AND 2021. THE INSTITUTE DID NOT RECOGNIZE A CHANGE IN LIABILITY FOR UNRECOGNIZED TAX BENEFITS (THE DIFFERENCE BETWEEN A TAX POSITION TAKEN, OR EXPECTED TO BE TAKEN, IN A TAX RETURN AND THE BENEFIT RECOGNIZED AND MEASURED IN THE FINANCIAL STATEMENTS). THERE WERE NO LIABILITIES FOR UNRECOGNIZED TAX BENEFITS AT JUNE 30, 2022 AND 2021. Schedule D, Part XI, Line 4(b) Other revenues in form 990 not in audited financial statements ROUNDING - 367 Schedule D, Part XII, Line 4(b) Other expenses in form 990 not in audited financial statements ROUNDING - 237 Europe (Including Iceland and Greenland) 18 Program Services SPECIFIC PROGRAM SERVICE ACTIVITY IN ALL REGIONS IS AGENTS ATTENDING AND/OR SPEAKING AT SCIENTIFIC CONFERENCES AND COLLABORATIONS. 56296 East Asia and the Pacific 2 Program Services SPECIFIC PROGRAM SERVICE ACTIVITY IN ALL REGIONS IS AGENTS ATTENDING AND/OR SPEAKING AT SCIENTIFIC CONFERENCES AND COLLABORATIONS. 132 Central America and the Caribbean 2 Program Services SPECIFIC PROGRAM SERVICE ACTIVITY IN ALL REGIONS IS AGENTS ATTENDING AND/OR SPEAKING AT SCIENTIFIC CONFERENCES AND COLLABORATIONS. 5819 South America 2 Program Services SPECIFIC PROGRAM SERVICE ACTIVITY IN ALL REGIONS IS AGENTS ATTENDING AND/OR SPEAKING AT SCIENTIFIC CONFERENCES AND COLLABORATIONS. 12951 North America (Canada & Mexico only) 0 Program Services SPECIFIC PROGRAM SERVICE ACTIVITY IN ALL REGIONS IS AGENTS ATTENDING AND/OR SPEAKING AT SCIENTIFIC CONFERENCES AND COLLABORATIONS. 1565 Central America and the Caribbean 0 0 Investments 4674542 0 24 0 0 0 24 4751305 0 4751305 true false true true true false Schedule F, Part I, Line 3 Method used to account for expenditures on org's financial statements CENTRAL AMERICA AND THE CARIBBEAN-Accrual,; EAST ASIA AND THE PACIFIC-Accrual; EUROPE (INCLUDING ICELAND AND GREENLAND)-Accrual; NORTH AMERICA (CANADA & MEXICO ONLY; SOUTH AMERICA-Accrual X X X true true X X X X X X false true false false false false false true false KRISTIINA VUORI MD PHD PRESIDENT 752467 0 231754 0 1930 0 29000 0 24567 0 1039718 0 0 0 C RANDAL MILLS PHD CEO (PART YEAR) 870105 0 318500 0 1714 0 229000 0 39556 0 1458875 0 0 0 SCOTT TOCHER GENERAL COUNSEL & CORPORATE SECRETARY 179287 0 14341 0 1091 0 0 0 7469 0 202188 0 0 0 AMAR DUVVUR CFO 199296 0 212705 0 420 0 0 0 8944 0 421365 0 0 0 MICHAEL JACKSON PHD DRUG DISCOVERY & DEV, SR VP 402299 0 41798 0 4156 0 29000 0 31058 0 508311 0 0 0 CARL WARE PHD CENTER DIRECTOR, IIDC 389104 0 40109 0 21729 0 29000 0 16465 0 496407 0 0 0 RANDAL KAUFMAN PHD PROGRAM DIRECTOR 373817 0 0 0 5102 0 29000 0 36980 0 444899 0 0 0 CHUN JEROLD PHD PROFESSOR 338613 0 17367 0 4156 0 29000 0 24624 0 413760 0 0 0 ZE'EV RONAI PHD CENTER DIRECTOR 401885 0 42001 0 5665 0 29000 0 39556 0 518107 0 0 0 Schedule J, Part I, Line 1a First-class or charter travel FIRST CLASS TRAVEL IS GENERALLY NOT PERMITTED, EXCEPT UNDER VERY LIMITED AND RARE CIRCUMSTANCES AND CONDITIONS, SUCH AS A MEDICAL CONDITION REQUIREMENT AND URGENT CIRCUMSTANCES. THIS WAS NOT TREATED AS TAXABLE COMPENSATION. Schedule J, Part I, Line 1a Tax indemnification and gross-up payments RELOCATION COSTS WERE GROSSED UP FOR OUR CEO, C. RANDAL MILLS. Schedule J, Part I, Line 1a Health or social club dues or initiation fees HEALTH OR SOCIAL CLUB DUES ARE NEGOTIATED IN THE HIRING PROCESS FOR CERTAIN EMPLOYEES. THE AMOUNTS WERE TREATED AS TAXABLE COMPENSATION. Schedule J, Part I, Line 4b Supplemental nonqualified retirement plan THE PARTICIPANT OF THE 457(F) DEFERRED COMPENSATION PLAN IS C. RANDAL MILLS. VESTING FOR C. RANDAL MILLS OCCURS THE EARLIEST OF 07/13/25, OR INVOLUNTARY TERMINATION WITHOUT CAUSE, OR PARTICIPANT'S RESIGNATION FOR GOOD CAUSE, OR THE DATE OF TERMINATION OF THE PLAN. DISTRIBUTION IS A ONE-TIME LUMP SUM PAYMENT UPON VESTING OF 100% OF THE VALUE OF THE PARTICIPANT'S INVESTMENT (COMPRISED OF INSTITUTE CONTRIBUTIONS TO THE CORPUS PLUS ANY INVESTMENT GAINS OR LOSSES THEREON). Schedule J, Part I, Line 7 Non-fixed payments SOME SENIOR EXECUTIVES HAVE EMPLOYMENT AGREEMENTS STIPULATING A BONUS WILL BE PAID TO THEM PROVIDED CERTAIN GOALS OR ACCOMPLISHMENTS ARE ACHIEVED. A COUNTY OF SAN DIEGO 956000934 79742YAQ5 2015-11-12 61963256 REFINANCE 2006 AND 2012 BONDS WITH ISSUE DATES OF 02/01/2006 AND 11/15/2012 , RESPECTIVELY. false false false A 0 21783870 61963256 0 0 39890000 289386 0 0 0 0 0 2015 true false true true A false true true true true true 0.014 0.0 0.014 false false true A false true false false true false false false true A true Schedule K, Part V Different Procedures to Undertake Corrective Action Issuer name: COUNTY OF SAN DIEGO FOR THE BOND ISSUES LISTED IN PART I, THE ALTERNATIVE PERIOD USED FOR THE REPORTING REQUIREMENTS IN THIS SECTION IS THE TWELVE MONTHS ENDED DECEMBER 31, 2021. Form 990, Part I, Line 1 MISSION STATEMENT SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE CONDUCTS WORLD-CLASS, COLLABORATIVE RESEARCH DEDICATED TO FINDING CURES FOR HUMAN DISEASE, IMPROVING THE QUALITY OF LIFE, AND THUS CREATING A LEGACY FOR ITS EMPLOYEES, PARTNERS, DONORS, AND COMMUNITY. Form 990, Part III, Line 4a PROGRAM SERVICE ACCOMPLISHMENTS Form 990 - Part III, line 4 Program Service Accomplishments Sanford Burnham Prebys is an independent nonprofit medical research organization dedicated to uncovering the origins of disease and launching bold new strategies that lay the foundation for cures. Our Institute has deep expertise in fundamental biology and is one of the most comprehensive drug discovery centers in the nonprofit world. Cancer: Research reveals why more Black women die from breast cancer: Research from Sanford Burnham Prebys has revealed significant molecular differences between the breast cells of white and Black women that help explain why Black women experience higher breast cancer mortality. The findings, published February 8 in the journal Therapeutic Advances in Medical Oncology, suggest that changing current diagnostic and treatment strategies could help address the disparity. Some gene edits may favor cells with cancer-linked mutations: A comprehensive study-conducted by researchers at Sanford Burnham Prebys, the National Cancer Institute (NCI) and other groups-has shown that gene editing, specifically gene knockout (KO), with CRISPR -Cas9 can favor cells with mutated forms of genes linked to cancer. The findings highlight the need to monitor patients undergoing CRISPR-Cas9-based gene therapy for cancer-related mutations. The study was published in the journal Nature Communications. Researchers identify a novel player in acute myeloid leukemia: A study led by scientists at Sanford Burnham Prebys has shown that the protein RNF5 plays an unusual role in acute myeloid leukemia (AML). Unlike its expected role, marking aberrant proteins for destruction, RNF5 binds with a second cell protein called RBBP4 to control expression of genes implicated in AML. These findings, published in Nature Communications, have important implications for improving AML patient outcomes. Boosting immunotherapy in aggressive brain cancer: Researchers from Sanford Burnham Prebys have collaborated the University of Pittsburgh Cancer Institute to reveal a new approach to enhance the effects of immunotherapy in glioblastoma, one of the most aggressive and treatment-resistant forms of brain cancer. The study, published recently in Cancer Discovery, describes a novel method to 'turn off' cancer stem cells-the malignant cells that self-renew and sustain tumors-enabling the body's own defense system to take charge and destroy tumors. Sanford Burnham Prebys drug enters Phase 1 study for the treatment of tobacco use disorder: A drug discovered in the lab of Nicholas Cosford, Ph.D., has entered a Phase 1 clinical study. The compound, SBP-9330, targets a neuronal signaling pathway underlying addictive behaviors and would be a first-in-class oral therapeutic to help people quit smoking. The study is being funded by the National Institute on Drug Abuse (NIDA) at the National Institutes of Health (NIH) through a grant awarded to Sanford Burnham Prebys, the Department of Psychiatry, University of California San Diego, School of Medicine, and Camino Pharma, LLC, who will oversee activities related to the Phase 1 study. Degenerative Diseases: Sanford Burnham Prebys unravels mysteries of the aging Down syndrome brain In the first study of its kind, researchers from Sanford Burnham Prebys have uncovered molecular changes within the aging brains of individuals with Down syndrome that could help explain their cognitive challenges, including the uniform development of Alzheimer's disease in these individuals later in life. The findings, published in the Proceedings of the National Academy of Science, could help pave the way for new therapies to aid people with Down syndrome and Alzheimer's disease. How Sanford Burnham Prebys is helping map the brain: Researchers in the lab of Sanford Burnham Prebys professor Jerold Chun, M.D., Ph.D., have helped the NIH create a cellular atlas of the motor cortex - the area of the brain responsible for movement. Their work, published recently in the journal Nature, is the flagship paper for the NIH's BRAIN initiative, a massive multi-institution project to unravel the mysteries of the human brain. Human Genetics: New stem cell identified by Sanford Burnham Prebys researchers offers hope to people with rare liver disease. Researchers from Sanford Burnham Prebys have discovered a new source of stem cells just outside the liver that could help treat people living with Alagille syndrome, a rare, incurable genetic disorder in which the bile ducts of the liver are absent, leading to severe liver damage and death. The findings, published recently in the journal Hepatology, have extensive biomedical implications for Alagille syndrome and for liver disease in general, including cancer. Biomarker could help diagnosis schizophrenia at an early age: Scientists at Sanford Burnham Prebys have discovered how levels of a protein could be used in the future as a blood-based diagnostic aid for schizophrenia. The activity of the protein, which is found in both the brain and blood, affects neural connections in human brains and is uniquely imbalanced in people diagnosed with the condition. The research also provides guidance for future analyses into the molecular basis of this serious, disabling mental disorder. The study was published in Proceedings of the National Academy of Sciences (PNAS). This enzyme is one of the hardest working proteins in the body: Researchers from Sanford Burnham Prebys have shown that a protein they identified plays a major role in the breakdown of hyaluronic acid, a compound found in the scaffolding between our cells. The findings, published recently in the Journal of Biological Chemistry, could have implications for epilepsy, cancer and other human diseases associated with hyaluronic acid and similar compounds. Immunity and Pathogenesis: Study finds promising therapeutic target for colitis: An international research group, led by Jamey Marth, Ph.D., a professor at Sanford Burnham Prebys, has shown that the Neuraminidase 3 (Neu3) enzyme is responsible for the onset and progression of colitis-a chronic digestive disease caused by inflammation of the colon. The study, recently published in the Proceedings of the National Academy of Sciences, represents a scientific advance toward a targeted therapy to help the millions of people worldwide affected by the disorder. Without this protein, tuberculosis is powerless: Sanford Burnham Prebys researchers have uncovered the structure of an important protein for the growth of tuberculosis bacteria. The study, published recently in Nature Communications, sheds light on an unusual metabolic system in tuberculosis, which could help yield new treatments for the disease and help make existing therapies more effective. How our immune system controls gut microbes: Sanford Burnham Prebys researchers including Carl Ware, Ph.D., and John ed, Ph.D., have discovered an immunological process in the gut that could help improve treatment for autoimmune and gastrointestinal diseases. The study, published March 22 in Cell Reports, found that this process regulates the activation of white blood cells in the intestines, which ultimately helps the body control the composition of the gut microbiome. New COVID-19 drug passes phase 2 clinical trial: In a phase 2 clinical trial conducted by Avalo and supported by Sanford Burnham Prebys, a significantly higher proportion of hospitalized patients with COVID-19 remained alive and free of respiratory failure for 28 days after receiving treatment with the new antibody, called CERC-002. Unlike other experimental COVID therapies, CERC-002 does not target the virus itself, instead targeting the immune response associated with the virus to stop the disease from progressing before it becomes fatal. Sanford Burnham Prebys and Roche fight back against antibiotic resistance: Researchers from Sanford Burnham Prebys have teamed up with prominent drug developer Roche Pharma to learn how bacteria develop antibiotic resistance. Their new results, published in the journal mBio, are one piece of a long-standing collaboration between the two organizations, the goal of which is to mitigate the growing threat of antibiotic resistance by developing more "irresistible" drugs and by helping improve antibiotic prescribing practices. Form 990, Part VI, Line 11b Review of form 990 by governing body PROCESS USED BY MANAGEMENT AND/OR GOVERNING BODY TO REVIEW FORM 990: THE 990 IS PREPARED BY THE FINANCE DEPARTMENT. IT IS REVIEWED BY THE INSTITUTE'S TAX ADVISORS, SELECTED MEMBERS OF MANAGEMENT INCLUDING THE CFO AND AUDIT COMMITTEE, AND PROVIDED TO MEMBERS OF THE BOARD PRIOR TO FILING. Form 990, Part VI, Line 12c Conflict of interest policy DESCRIPTION OF PROCESS TO MONITOR TRANSACTIONS FOR CONFLICT OF INTEREST: SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE HAS A CONFLICT OF INTEREST POLICY THAT REQUIRES ALL TRUSTEES, PRINCIPAL OFFICERS OR MEMBERS OF A COMMITTEE WITH BOARD DELEGATED POWERS TO ANNUALLY CONFIRM THEIR RECEIPT OF THE CONFLICT OF INTEREST POLICY AND DISCLOSE ANY NEW ASSOCIATIONS OR INTERESTS THAT MIGHT POTENTIALLY POSE A CONFLICT. THIS IS A WRITTEN CONFIRMATION THAT SHE OR HE READ AND UNDERSTANDS THE CONFLICT OF INTEREST POLICY, WILL ABIDE BY THE CONFLICT OF INTEREST POLICY AND CERTIFIES DISCLOSURE OF ALL INTERESTS OR RELATIONSHIPS THAT MAY POSE CONFLICTS. IN ADDITION, EACH YEAR NEW TRUSTEES RECEIVE TRAINING REGARDING THE INSTITUTE'S CONFLICT OF INTEREST POLICY, WHICH INCLUDES HOW TO IDENTIFY A CONFLICT OF INTEREST AND HOW TO HANDLE POSSIBLE CONFLICTS OF INTEREST WHEN THEY ARISE. THE COMPLIANCE DEPARTMENT REVIEWS EACH OF THE STATEMENTS AND ASSESSES WHETHER AN ACTUAL OR POTENTIAL CONFLICT OF INTEREST EXISTS/MAY EXIST AND WHETHER THE INDIVIDUAL SHOULD BE PROHIBITED FROM CONSIDERATION OF RELATED ITEMS. ANY TRUSTEE, PRINCIPAL OFFICER OR MEMBER OF A COMMITTEE WITH BOARD DELEGATED POWERS WITH A CONFLICT IN A MATTER REQUIRING ACTION BY THE BOARD ARE PROHIBITED FROM PARTICIPATING IN THE BOARD'S DELIBERATIONS AND/OR VOTING ON THE PARTICULAR TRANSACTION OR MATTER IN WHICH HE OR SHE HAS AN INTEREST; AND OTHERWISE REFRAIN FROM EXERTING ANY INFLUENCE TO AFFECT A DECISION. HOWEVER, OTHER MEASURES MAY BE REQUIRED, DEPENDING ON THE NATURE OF AND THE ABILITY TO REASONABLY MANAGE A CONFLICT. Form 990, Part VI, Line 15a Process to establish compensation of top management official PROCESS FOR DETERMINING COMPENSATION: COMPENSATION FOR THE CEO, THE PRESIDENT, CHIEF FINANCIAL OFFICER, AND OTHER KEY EMPLOYEES IS ESTABLISHED ACCORDING TO INSTITUTE POLICIES WHICH ARE DESIGNED TO MEET THE IRS STANDARD FOR "REBUTTABLE PRESUMPTION OF REASONABLENESS". THE COMPENSATION COMMITTEE OF THE BOARD OF TRUSTEES, CONSISTING OF THREE INDEPENDENT TRUSTEES, REVIEWS COMPARABILITY DATA AT LEAST EVERY TWO YEARS PROVIDED BY AN INDEPENDENT EXTERNAL CONSULTANT/RESOURCE THAT INCORPORATES AND EVALUATES INSTITUTE DATA AND THAT OF COMPARABLE ORGANIZATIONS AND MARKETS FROM WHICH THE INSTITUTE DRAWS ITS EXECUTIVE TALENT. UTILIZING THIS INFORMATION, THE COMPENSATION COMMITTEE, WHICH TYPICALLY SEEKS TO ESTABLISH COMPENSATION BETWEEN THE 50TH AND THE 75TH PERCENTILE OF THE COMPARABILITY DATA, MAKES A DETERMINATION WHETHER THE PROPOSED COMPENSATION IS REASONABLE. THE COMPENSATION COMMITTEE HAS BEEN DELEGATED AUTHORITY BY THE BOARD OF TRUSTEES TO REVIEW AND APPROVE COMPENSATION OF ALL POSITIONS EXCEPT FOR THE CEO. THE CEO'S COMPENSATION PACKAGE IS REVIEWED AND APPROVED INITIALLY BY THE COMPENSATION COMMITTEE AND THEN GOES TO THE EXECUTIVE COMMITTEE FOR FINAL APPROVAL. THE COMPENSATION COMMITTEE CONTEMPORANEOUSLY AND ADEQUATELY DOCUMENTS THE BASIS FOR ITS DETERMINATION AND RECOMMENDATION TO THE EXECUTIVE COMMITTEE. IF APPROVED BY THE EXECUTIVE COMMITTEE, THE CEO COMPENSATION PACKAGE IS THEN IMPLEMENTED AND SUCH DOCUMENTATION IS KEPT IN THE WRITTEN AND ELECTRONIC RECORDS OF THE BOARD OF TRUSTEES. THE PROCESS WAS LAST COMPLETED ON JUNE 10, 2021 FOR THE FOLLOWING POSITIONS: 1) PRESIDENT 2) CAO/CFO 3) VP BUSINESS DEVELOPMENT 4) VP PHILANTHROPY 5) SVP DRUG DISCOVERY & DEVELOPMENT 6) PROGRAM DIRECTOR/PROFESSOR 7) CANCER CENTER DIRECTOR/PROFESSOR 8) INFECTIOUS & INFLAMMATORY DISEASE CENTER DIRECTOR/PROFESSOR Form 990, Part VI, Line 15b Process to establish compensation of other employees see above Form 990, Part VI, Line 19 Required documents available to the public PROCESS FOR MAKING DOCUMENTS AVAILABLE TO THE PUBLIC DOCUMENTS ARE AVAILABLE UPON REQUEST Form 990, Part VIII, Line 11d Other Miscellaneous Revenue - Total Revenue: 6000, Related or Exempt Function Revenue: 6000, Unrelated Business Revenue: , Revenue Excluded from Tax Under Sections 512, 513, or 514: ; Schedule F, Part I, Line 3 Program Service Activities Sanford Burnham Prebys Medical Discovery Institute does not maintain ongoing operations in foreign jurisdictions. However, the Institute's scientist do travel to various scientific conferences in other countries to share the Institute's scientific discoveries, as well as, to learn from other scientists across the world. Schedule F, Part I, Line 3(e) Type of Service Specific Program Service Activity in all regions is agents attending and/or speaking at scientific conferences and collaborations. Schedule F, Part I, Line 3(f) Accounting Method The accrual method of accounting was used to determine the amounts in Part I, line 3, column F.